New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
Systemic mastocytosis (SM) has greatly benefited from the broad application of precision medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape of SM variants have be...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
27 February 2020
|
| In: |
Blood
Year: 2020, Jahrgang: 135, Heft: 16, Pages: 1365-1376 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2019000932 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2019000932
|
| Verfasserangaben: | Andreas Reiter, Tracy I. George, and Jason Gotlib |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1703745302 | ||
| 003 | DE-627 | ||
| 005 | 20230426114707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200706s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2019000932 |2 doi | |
| 035 | |a (DE-627)1703745302 | ||
| 035 | |a (DE-599)KXP1703745302 | ||
| 035 | |a (OCoLC)1341344397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 245 | 1 | 0 | |a New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis |c Andreas Reiter, Tracy I. George, and Jason Gotlib |
| 264 | 1 | |c 27 February 2020 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.07.2020 | ||
| 520 | |a Systemic mastocytosis (SM) has greatly benefited from the broad application of precision medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape of SM variants have been critical adjuncts to the diagnosis and subclassification of SM, and development of clinical-molecular prognostic scoring systems. Multilineage KIT involvement and multimutated clones are characteristic of advanced SM (advSM), especially SM with an associated hematologic neoplasm (AHN). A major challenge is how to integrate conventional markers of mast cell disease burden (percentage of bone marrow mast cell infiltration and serum tryptase levels) with molecular data (serial monitoring of both KIT D816V variant allele frequency and NGS panels) to lend more diagnostic and prognostic clarity to the heterogeneous clinical presentations and natural histories of advSM. The approval of the multikinase/KIT inhibitor midostaurin has validated the paradigm of KIT inhibition in advSM, and the efficacy and safety of second-generation agents, such as the switch-control inhibitor ripretinib (DCC-2618) and the D816V-selective inhibitor avapritinib (BLU-285) are being further defined in ongoing clinical trials. Looking forward, perhaps the most fruitful marriage of the advances in molecular genetics and treatment will be the design of adaptive basket trials that combine histopathology and genetic profiling to individualize treatment approaches for patients with diverse AHNs and relapsed/refractory SM. | ||
| 650 | 4 | |a allele burden | |
| 650 | 4 | |a c-kit mutation | |
| 650 | 4 | |a cell transplantation | |
| 650 | 4 | |a classification | |
| 650 | 4 | |a d816v | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a mast-cells | |
| 650 | 4 | |a midostaurin | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a George, Tracy I. |e VerfasserIn |0 (DE-588)1213262100 |0 (DE-627)1703746368 |4 aut | |
| 700 | 1 | |a Gotlib, Jason |e VerfasserIn |0 (DE-588)1159581398 |0 (DE-627)1022260103 |0 (DE-576)505048515 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 135(2020), 16, Seite 1365-1376 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis |
| 773 | 1 | 8 | |g volume:135 |g year:2020 |g number:16 |g pages:1365-1376 |g extent:12 |a New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2019000932 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200706 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1703745302 |e 3695813474 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"part":{"issue":"16","year":"2020","extent":"12","pages":"1365-1376","text":"135(2020), 16, Seite 1365-1376","volume":"135"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"titleAlt":[{"title":"Blood online"}],"origin":[{"publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedKey":"1946"}],"note":["Gesehen am 21.04.2023"],"pubHistory":["1.1946 -"],"recId":"266886647","disp":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosisBlood","type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["266886647"],"zdb":["1468538-3"],"issn":["1528-0020"]},"corporate":[{"role":"isb","display":"American Society of Hematology"}],"language":["eng"]}],"person":[{"family":"Reiter","display":"Reiter, Andreas","given":"Andreas","role":"aut"},{"role":"aut","display":"George, Tracy I.","family":"George","given":"Tracy I."},{"display":"Gotlib, Jason","family":"Gotlib","given":"Jason","role":"aut"}],"title":[{"title_sort":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis"}],"physDesc":[{"extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1703745302"],"doi":["10.1182/blood.2019000932"]},"language":["eng"],"origin":[{"dateIssuedDisp":"27 February 2020","dateIssuedKey":"2020"}],"note":["Gesehen am 06.07.2020"],"recId":"1703745302","name":{"displayForm":["Andreas Reiter, Tracy I. George, and Jason Gotlib"]}} | ||
| SRT | |a REITERANDRNEWDEVELOP2720 | ||